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RNA interference technology is an ideal strategy to elucidate the mechanisms associated with human CD34+ hematopoietic
stem cell diﬀerentiation into dendritic cells. Simple manipulations in vitro can unequivocally yield alloreactive or tolerogenic
populations,suggestingkeyimplicationsofbiochemicalplayersthatmightemergeastherapeutictargetsforcancerorgraft-versus-
host disease. To knockdown proteins typically involved in the biology of dendritic cells, we employed an siRNA delivery system
based on the cationic liposome DOTAP as the carrier. Freshly-isolated CD34+ cells were transfected with siRNA for cathepsin
S with negligible cytotoxicity and transfection rates (>60%) comparable to the eﬃciency shown by lentiviral vectors. Further,
cathepsin S knockdown was performed during both cell commitment and through the entire 14-day diﬀerentiation process
with repeated transfection rounds that had no eﬀect per se on cell development. Tested in parallel, other commercially-available
chemical reagents failed to meet acceptable standards. In addition to safe and practical handling, a direct advantage of DOTAP
over viral-mediated techniques is that transient silencing eﬀects can be dynamically appraised through the recovery of targeted
proteins. Thus, our ﬁndings identify DOTAP as an excellent reagent for gene silencing in resting and diﬀerentiating CD34+ cells,
suggesting a potential for applications in related preclinical models.
Copyright © 2009 Sabata Martino et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The discovery of siRNAs and subsequent advances in
RNA interference (RNAi) technology has contributed to
a major methodological shift in functional genomics [1].
Gene silencing, that can be successfully extended to high-
throughput screening formats [2, 3], is a procedure that
directly accelerates biological and biomedical research
through the identiﬁcation of molecular players involved
in development, homeostasis, and disease. In the new
millennium, the explosive growth of this ﬁeld has also raised
the prospect of RNAi as a therapeutic to treat a wide range
of pathologies, in particular viral infections, cancer, and
neurodegenerative disorders [4–7].
Synthetic siRNAs have emerged as a widespread means
for gene silencing in mammalian cells [8], notwithstand-
ing limitations associated with a nonrenewable supply,
temporary silencing eﬀect, and occurrence of oﬀ-target
activity [9, 10]. Next-generation synthetic products were
recently introduced to ensure the highest silencing power
under a minimal occurrence of false positives (e.g., ON-
TARGETplus [Dharmacon] and Silencer Select validated
siRNAs [Ambion]), and provide the opportunity to transfect
virtually any cell type in the absence of a carrier (Accell
siRNAs [Dharmacon]). Further, shRNA expression vectors
coupled to lentiviral transduction systems were developed
to obtain unlimited resources, achieve stable integration
into the genome in a widest variety of both dividing and
nondividing cells, produce sustained transgene expression,
and comply with in vivo applications (e.g., MISSION
[Sigma-Aldrich], BLOCK-iT [Invitrogen], SMARTvector
[Dharmacon], GeneNet [System Biosciences], and Lenti-X2 Journal of Biomedicine and Biotechnology
[Clontech]) [11–13]. Finally, access to mimic and inhibitor
miRNA libraries for use in either gain- or loss-of-function
analyses, respectively, have enhanced scope and ﬂexibility of
studiesintendedtounraveltheinvolvementofmiRNAs(e.g.,
PremiR [Ambion], miRIDIAN [Dharmacon], and miScript
[Qiagen]) in cytoplasmic posttranscriptional gene silencing
[14],translationalactivation[15]andtranscriptionalcontrol
of gene expression in the nucleus [16].
However, the extraordinary beneﬁts of these break-
throughs in RNAi technology may imply signiﬁcant research
investments and special requirements, such as biocontain-
ment facilities dedicated to viral work. Chemical agents,
instead, are relatively inexpensive, easy to handle and
generally already optimized by the vendor for use with spe-
ciﬁc cell lines. Nonetheless, chemical transfections in ﬁnite
cultures or freshly-isolated primary cells usually raise major
challenges due to a combination of cytotoxic eﬀects and
poor transfection eﬃciencies. These problems become more
obvious in dynamic systems such as stem cells subjected to
diﬀerentiation.
Lentiviral vectors can successfully transduce hematopoi-
etic stem cells (HSCs) [12, 17], but integrate stably in
the genome and preclude the recovery of knocked-down
proteins. Within nonviral transfection methods for HSCs,
electroporation raises major survival issues due to apoptotic
cell death [18], while nucleofactor technology was shown
to deliver mRNA and plasmid DNA with inconsistent
transfection and cell survival rates [19].
Lipofection has typically been considered ineﬃcient
for use with HSCs [20]. Nonetheless, based on the large
number of products currently available from vendors and
the advantages oﬀered by a transient gene knockdown,
we screened a variety of agents with diﬀerent chemical
formulations and found that the liposomal version of the
monocationic lipid DOTAP is an excellent vector for the
treatment of freshly isolated HSCs. Further, we observed that
DOTAP is an eﬃcient vehicle for gene knockdown in HSCs
induced to diﬀerentiate into immunogenic dendritic cells in
vitro through a conventional treatment based on Flt3L, GM-
CSF, IL-4 and TNF-α [21–23].
2.MaterialsandMethods
2.1. Isolation of Human HSCs. Blood samples were collected
from healthy volunteers who provided informed consent.
Human peripheral blood mononuclear cells were isolated
by density gradient centrifugation over Ficoll-Paque PLUS
(GE Healthcare), after which CD34+cells were puriﬁed
by immunomagnetic selection using the minimagnetic-
activated cell sorter (MACS) system (Miltenyi Biotec). Mean
purityofCD34-enrichedcells,determinedbyﬂowcytometry
using a FACScan (BD Biosciences), was 94.8%, with a
median value of 92 throughout an 86–98.5 range.
2.2. Diﬀerentiation of HSCs into Dendritic Cells. To generate
immunogenic dendritic cells, CD34-enriched cells were
transferred to 25cm2 ﬂasks at a density of 105 cells/mL and
cultured for 14 days in RPMI-1640 medium (Euroclone)
containing 10% fetal calf serum (FCS) (Euroclone) and a
cytokine cocktail composed of human recombinant, Flt3L
(50ng/mL), GM-CSF (50ng/mL), IL-4 (10ng/mL), and
TNF-α (2.5ng/mL) (PeproTech EC). Every third day, half
of the culture medium was replaced by fresh medium
supplemented with the same cocktail. Cells were analyzed at
day 3, 7, and 14 to evaluate the expression of speciﬁc markers
of diﬀerentiation [23].
2.3. Evaluation of Diﬀerent Reagents for siRNA Transfection
of Untreated CD34+ Stem Cells. Thefollowing,commercially
a v a i l a b l er e a g e n t sw e r et e s t e dt od e t e r m i n et r a n s f e c t i o nr a t e s
andcytotoxicityeﬀects:TransPassR1andTransPassR2(New
England Biolabs), Lipofectamine 2000 and Lipofectamine
LTX (Invitrogen), siPORT NeoFX and siPORT Amine
(Ambion), and DOTAP (Roche). Tests were performed using
a 96-well plate format. Freshly prepared CD34+ cells were
seededatadensityof2×104/well.Fluorescein-labeledsiRNA
control (New England Biolabs), in a ﬁnal concentration of
15nM, was used to monitor the transfection procedures.
Fluorescein-labeled siRNA was regularly diluted with RPMI-
1640 without serum, except for the experiment performed
with DOTAP, in which the diluent was HBS (Hepes-buﬀered
saline: 20mM HEPES, pH 7.4, containing 150mM NaCl).
The transfection reagents were essentially employed as
per each vendor’s recommendations. TransPass R1 and
TransPassR2(0.2μL)werediluteddirectlyintheﬂuorescein-
labeled siRNA solution (10μL), incubated 30 minutes at
room temperature and then added to the cultures (90μL).
Lipofectamine 2000 and Lipofectamine LTX (0.25μL) were
ﬁrst diluted in 12.5μL RPMI-1640 without serum and, after
5 minutes incubation, mixed with 12.5μL of ﬂuorescein-
labeled siRNA. After 30 minutes incubation, the transfection
complexes were added to the cells (75μL).
siPORT NeoFX and siPORT Amine were ﬁrst diluted
(0.5 and 0.3μL, resp.) in 10μL RPMI-1640 without serum.
After 10 minutes at room temperature, each carrier was
mixedwith10μLofﬂuorescein-labeledsiRNA.Themixtures
(20μL) were incubated 10 minutes, then spotted in the assay
wells. Within 5 minutes, cells were dispensed in a volume of
80μL.
DOTAP (1.4μL) was diluted in 7μL HBS and then
mixed, very slowly, with the same volume of ﬂuorescein-
labeled siRNA. After 30 minutes at room temperature, the
mixture was added to cells (186μL) resuspended in RPMI-
1640 containing 20% FCS.
Except for the experiment performed with DOTAP, fresh
medium was added to the assay wells 4 hours after each
transfection process in order to achieve a ﬁnal volume and
a concentration of FCS of 200μL and 10%, respectively.
In all instances, transfection and cell survival were
evaluated 24 hours after the transfection method.
Transfection rates were expressed as the ratio between
transfected (ﬂuorescein-labeled) and total number of viable
cells measured via DAPI nuclear staining and trypan blue
exclusion test. Signals were captured by a Nikon Eclipse
TE2000-S ﬂuorescence microscope equipped with a Cell-
F video camera (Olympus) and processed via the Cell-F
software.Journal of Biomedicine and Biotechnology 3
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Figure 1: Eﬀects of siRNA delivery agents on cytotoxicity and transfection rates. Freshly isolated HSCs were subjected to agent-speciﬁc
transfection protocols using a ﬂuorescein-labeled, nontargeting siRNA control as described in the Materials and Methods. After 24 hours
incubation, cytotoxicity was assessed through the trypan blue dye exclusion test (a), while transfection rates were calculated from the ratio
between ﬂuorescein-labeled and total number of DAPI-stained cells (b). Data shown are representative of triplicate determinations.
2.4. Silencing of Cathepsin S Gene via the DOTAP Reagent
in HSCs Subjected to Diﬀerentiation. Freshly isolated CD34+
cellswereresuspendedinRPMI-1640supplementedwiththe
agents used to generate immunogenic dendritic cells. Imme-
diately after treatment, cells were subjected to transfection
using a predesigned siRNA targeting the CatS gene (CTSS:
ID-113084-113085, Ambion).
Cells subjected to mock- and scrambled-siRNA trans-
fection (ID-46183G, Ambion) under the same experimental
conditions were employed for control purposes. The pro-
cedure, run in a 24-well plate format via triplicate tests,
was implemented using a 25nM ﬁnal siRNA concentration.
Each well-contained 2 × 105 cells in a volume of 500μL.
The siRNAs were combined with DOTAP and maintained
for 30 minutes at room temperature to form complexes.
The mixture (50μL) was then overlaid dropwise on the cell
cultures.Following4-hourincubation,1.2mLofRPMI-1640
containing 10% FCS and diﬀerentiating agents was added to
each well. To ensure silencing of genes for the entire 14-day
diﬀerentiation process, cells were centrifuged, resuspended
in 500μL of cytokine-enriched culture medium and exposed
to a second (day 3) and third (day 9) transfection round
under the same experimental conditions.
2.5. Western Blotting. Preparation of cell extracts, elec-
trophoresis (12% gel) under reducing conditions and
Western blotting procedures were performed as previously
described [24].
Precursors and mature forms of cathepsin S were ana-
lyzed using polyclonal antibodies from Santa Cruz Biotech-
nology as the primary antibodies. Immunodetection was
carried out by employing the enhanced, chemiluminescent
Amersham ECL Plus kit. For each blot, several time expo-
sures were performed to conﬁrm that the results were within
the linear response range of the ﬁlm. Densitometric scans
via an MCID system (InterFocus Imaging) were used to
demonstrate that the intensity of the bands was proportional
to protein content.
3. Results and Discussion
Several transfection reagents were employed to evaluate
cytotoxic eﬀects and the capacity to deliver a ﬂuorescein-
labeled siRNA control in freshly isolated, untreated HSCs.
Commercially-available agents were chosen to explore a
variety of structural diversities and chemical formulations
as per each vendor’s product description. The screen
included a cationic lipid (TransPass R1), a nonlipid
cationic polymer (TransPass R2), a lipid-based formula-
tion designed for reverse transfection protocols (siPORT
NeoFX), a polyamine mixture (siPORT Amine), and
diﬀerent versions of cationic liposomes (Lipofectamine
2000, Lipofectamine LTX), an animal origin-free product,
and DOTAP, obtained from N-[1-(2,3-Dioleoyloxy)propyl]-
N,N,N-trimethylammonium methylsulfate.
Fourchemicals(i.e.,LipofectamineLTX,siPORTNeoFX,
siPORTAmine,andDOTAP)wererelativelywelltoleratedby
HSCs (≥85% viability) (Figure 1(a)), however only DOTAP
was found to combine a lack of cell cytotoxicity with eﬃcient
(60%) siRNA transfer (Figure 1(b)). TransPass R2 showed4 Journal of Biomedicine and Biotechnology
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Figure 2: Cell viability during repeated, DOTAP-mediated trans-
fection rounds in diﬀerentiating HSCs. Freshly isolated HSCs
were induced to diﬀerentiate into immunogenic dendritic cells
as described in the Materials and Methods. Immediately after
treatment, cultures were split into two cell populations, of which
one, used as the control, was grown in absence of manipulations
(white bars), while the other was subjected to two and three
DOTAP-based, scrambled siRNA transfection rounds performed at
day 0 and day 3 (black bars), and day 0, day 3 and day 9 (grey bars).
Cell viability was monitored by trypan blue staining at diﬀerent
time points as indicated.
a transfection capacity similar to DOTAP, but signiﬁcant
cytotoxicity. Thus, DOTAP emerged as the chemical with
suitable attributes for use in gene knockdown studies of
diﬀerentiating HSCs.
We have previously shown that changes in cathepsin
S expression correlate with the diﬀerentiation of HSCs
into immunogenic dendritic cells in vitro. In this regard,
cathepsin S shows a precursor form of 66KDa in freshly
isolated HSCs, while the conventional, mature protein of
26KDa appears following a 7-day treatment with a cytokine
cocktail [22]. Based on the physiological role of cathepsin
S in the biology of dendritic cells [25, 26], we employed a
gene knockdown strategy to investigate the involvement of
the enzyme during the entire 14-day diﬀerentiation process.
In light of the transient nature of siRNA-mediated
silencing, we implemented the DOTAP protocol for three
rounds of transfection performed in untreated HSCs (day
0) and, following cocktail treatment, in cells subjected to
diﬀerentiation for 3 and 9 days. Trypan blue exclusion tests
performed at diﬀerent time points showed that multiple
knockdowns did not aﬀect cell viability (Figure 2). Further-
more, overall metabolic activity and cell proliferation were
also unchanged, measured through reduction rates of the
tetrazoliumsaltXTT(notshown)[27].Wealsoobservedthat
repeated transfections of a scrambled siRNA had no impact
on the temporal expression of antigens typically modulated
during the diﬀerentiation of HSCs into phenotypically and
functionally mature dendritic cells, namely CD34, CD1a,
CD80, CD86, CD83, and CD11c (Figure 3). Similarly, the
expressionofadditionalimmunophenotypicmarkerssuchas
CD40(10.04%±0.5),CD4(59.02%±0.3),CD123(46.08%±
0.6) HLA-ABC (94.10% ± 0.7) in fully diﬀerentiated den-
dritic cells was found to compare well with previous data
[23], suggesting that the diﬀerentiation process advanced
normally within expected temporal timeframes. Further,
mixed lymphocyte reaction tests (not shown) did not reveal
any discrepancy in the functional properties of alloreactive
dendritic cells [23]. On day 14, the reduction of cathepsin
S expression exceeded 95% in the diﬀerentiation model, as
indicated by Western blotting analysis (Figure 4(a)). Instead,
gene silencing performed only twice at day 0 and, again,
at day 3 caused more than 80% enzyme reduction during
the cell commitment stage (day 7), followed by increasing
cathepsin levels that resulted in a fully restored expression
aftertwoweeks(Figure 4(b)).Interestingly,nodiﬀerenceson
the CD34, CD1a, CD80, CD86, CD83, and CD11c markers
were measured during HSCs diﬀerentiation subjected to two
and three transfection rounds compared to untrasfected cells
(Figure 3).
These results were found to be consistent throughout
the screen of >20 diﬀerent populations of freshly isolated
HSCs and therefore demonstrate a reliable and ﬂexible
experimental approach. This system was therefore explored
to study the biochemical implication of cathepsin S in the
molecular mechanisms associated with HSC diﬀerentiation
into dendritic cells along the immunogenic or immunosup-
pressive pathway (Martino et al., submitted manuscript).
Together, our ﬁndings point to DOTAP as a chemical
suitable for siRNA delivery into HSCs, in light of a trans-
fection eﬃciency (∼60%) comparable to the transduction
rate recently achieved in the same human cells through
lentiviral vectors [17], and the excellent tolerance to repeated
exposures. The ability to dramatically enhance antisense
oligodeoxyribonucleotide uptake had, in previous studies,
been taken as evidence for DOTAP’s biocompatibility with
HSCs [28]. However, absence of any disruption during HSC
diﬀerentiation further suggests that the DOTAP protocol
herein described may be successfully extended to other HSC-
related systems, including models aimed at addressing exist-
ing controversial perspectives on HSC transdiﬀerentiation
and overall plasticity [29, 30].
It is possible that other chemical agents, not included
in our screen, may exhibit a performance comparable, if
not better, to that produced by DOTAP. In this regard,
the cationic lipophosphoramide KLN-5 was shown to be
a nontoxic, highly eﬃcient vehicle for transgene delivery
into HSCs [31]; however, this chemical has not yet been
tested in repeated siRNA transfection procedures and, to
our knowledge, is not widely available through vendors.
It must be noted that while a large number of lipid
formulations could be designed to introduce nucleic acids
in cells, a complex combination of chemical-physical and
biological factors may severely limit the selection of chem-
icals capable of transfecting synthetic siRNAs with high
transfection scores in HSCs. Indeed, cationic liposomes such
as DOTAP, Lipofectamine 2000 and Lipofectamine LTXJournal of Biomedicine and Biotechnology 5
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Figure 3: Expression of phenotypic markers throughout HSC diﬀerentiation into immunogenic dendritic cells in presence of multiple, DOTAP-
mediated transfection rounds. HSCs were subjected to diﬀerentiation agents, and then immediately split into two parallel cultures, one of
which was maintained in the absence of manipulations, while the other was subjected to DOTAP-based, scrambled siRNA transfection
rounds.PhenotypicantigenstypicallymodulatedduringHSCdiﬀerentiationintoimmunogenicdendriticcellswereanalyzedinHSCsatday
0( white bars), day 3 (grey bars), and day 14 (black bars). In all instances, analyses were performed through a FACScan ﬂow cytometer using
monoclonal antibodies labeled with ﬂuorescein isothiocyanate or phycoerythrin. Data shown are representative of triplicate determinations.
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Figure 4: Silencing of cathepsin S during HSC diﬀerentiation. (a) Levels of cathepsin S were assessed by Western blotting in dendritic
cells generated from the diﬀerentiation in vitroof HSCs. During the 14-day diﬀerentiation process, cells were subjected to DOTAP-based
transfection rounds on day 0, 3, and 9 using a CTSS-targeting siRNA as described in the Materials and Methods. Untreated and scrambled
siRNA-transfected cells were employed for control purposes. Levels of precursor (66KDa) and mature (26KDa) forms of cathepsin S at
diﬀerent time points (i.e., days 7 and 14) are indicated. β-actin was used to normalize the signals. (b) Shown is the same analysis as in panel
A, except for the number of transfections, that were performed on day 0 and 3 only. Graphs are representative of experiments consistently
reproduced using at least 20 diﬀerent populations of HSCs.6 Journal of Biomedicine and Biotechnology
display a positively-charged headgroup that engages elec-
trostatic interactions with the sugar-phosphate backbone, a
spacer that may or may not be designed to facilitate such
interactions, and 1–3 hydrocarbon chains that may vary in
length, extent of saturation and distribution of cis and trans
conﬁgurations [32]. Thus, cationic liposomes can be subject
to a high degree of structural permutations, likely correlated
with a capacity to transfer nucleic acids in speciﬁc cell
types. Despite structural similarities and a shared clathrin-
mediated endocytosis process for DNA delivery [33, 34],
these reagents exhibited a very wide performance range
when tested in the HSC system. Marked diﬀerences in vector
eﬃciencies may also arise from diﬀerent mechanisms of
internalization linked to subsequent, intracellular traﬃcking
routes associated with macromolecular fates [33].
4. Conclusions
Our ﬁndings clearly point to DOTAP as an ideal vehicle for
in vitro studies that require gene expression modulation in
HSCs. It will, therefore, be intriguing to investigate whether
this reagent can also be adapted to in vivo applications,
for example, through combination with low-molecular-
weight polyethylenimines. These may indeed synergize with
liposomes for DNA uptake [35] and have already been
proven to be eﬀective in preclinical models [36, 37]. This
approach, if successful, would obviate the safety concerns
associated with viral-mediated insertional mutagenesis.
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